« Large genomic differences explain our little quirks | | Is Race Real? »
May 20, 2005
Genetics in the News
Costs of Medical IRBs Are Greater Than Previously Expected, Bioethics Study Shows Institutional review boards, the committees that oversee protections for human research participants, often come with a higher than expected price tag, according to results of a study published in the April 28 edition of the New England Journal of Medicine.
Neurotech Index
To help investors gauge the overall welfare on the public markets of companies specializing in neurotechnology, NeuroInsights has introduced NeuroInsights' Neurotech Index in the recently released strategic investment and market analysis report on the neurotechnology industry.
Concern over BRCA2 patent, European geneticists say changes would force them to ask whether women are Ashkenazi Jews
Some Jewish women in Europe could face discrimination in access to breast cancer diagnosis as a result of changes made to a patent for the gene BRCA2, owned by Utah-based firm Myriad Genetics, geneticists said at a meeting this week. They said that the changes could mean that women seeking testing would have to disclose whether they were Ashkenazi Jews, and might preclude testing in countries without testing licenses.
Gene therapy promises the holy grail
A new gene therapy technique, which is more than twice as effective as steroids at boosting muscle, will soon be given the go-ahead for testing on humans. After that, doctors say, it is inevitable that athletes will try to use it to enhance their performance.
Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women
The U.S. Preventive Services Task Force (USPSTF) recommends against the routine
use of combined estrogen and progestin for the prevention of chronic conditions
in postmenopausal women.
rsp10 May 20, 2005 01:21 PM